Drug Profile
QAF 805
Alternative Names: QAF-805Latest Information Update: 23 Feb 2012
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiasthmatics; Thiazoles
- Mechanism of Action Adenosine A2B receptor antagonists; Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 23 Feb 2012 Discontinued - Phase-I for Asthma in United Kingdom (unspecified route)
- 30 Apr 2007 Phase-I clinical trials in Asthma in United Kingdom (unspecified route)